Movember Foundation and Prostate Cancer Canada team up to turn research into results

Two major projects are underway to help men with aggressive disease



July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.

Each set to receive $1.5 million over a 3 year period, the objective of the projects is to accelerate the transition of existing knowledge into clinical application:
 


Targeting a protein that assists a deadly form of prostate cancer

Principal Investigator: Dr. Amina Zoubeidi, Vancouver Prostate Centre, Vancouver Coastal Health Research Institute

Dr. Zoubeidi and her team are focusing on a deadly form of prostate cancer called neuroendocrine prostate cancer (NEPC), for which the only treatment option is a highly toxic chemotherapy and survival is measured in months. Building upon the discovery of a protein that is essential for the growth and survival of NEPC, the team is developing first-in-field blockers of this protein. At the successful completion of this research, they will have fine-tuned an ideal drug that is ready for immediate application in a clinical trial, with the ultimate goal of changing the way NEPC is treated.

Bacteria as a prostate cancer drug delivery service

Principal Investigator: Sylvain Martel, Polytechnique Montréal

Dr. Martel and his team are focused on improving the accuracy and speed of drug-delivery to sites where prostate cancer cells have spread, which will lead to better theraputic effects while reducing toxicity for the patient. In order to accomplish this, they are proposing innovative delivery vehicles that have exceptional propulsion, sensory, and navigation capabilites - bacteria. Using special bacteria that cause no significant immunce response, they will conduct human-scale studies with the aim of introducing these natural nanorobots as key delivery agents in the treatment of prostate cancers.

"The road from research discoveries to real world impact can be long and winding, and it is for that very reason that projects such as these are so exciting," explained Dr. Stuart Edmonds, PCC's Vice President of Research, health Promotion and Survivorship. "After untold amounts of time, money and hard work, we are now in a position to cross the threshold from the lab to the clinic and begin applying the sum total of this research towards improving outcomes for men and their families."

Paul Villanti, the Movember Foundation's Director of Programmes, said "The Movember Foundation's mission is to stop men dying too young, and these two pioneering projects represent an incredible opportunity to do exactly that. It is only through the efforts of our amazing community of fundraisers in Canada that we are in a position to take these promising new treatment methods for men from the lab that vital step closer to clinical practice. We are hugely grateful to these incredible individuals who make such a difference.

About the Movember Foundation

The Movember Foundation is the leading men's health charity, funding over 1,200 projects in 21 countries worldwide -- focused on men's mental health, suicide prevention, testicular and prostate cancer research, and support. To date, Movember has raised over $800 million worldwide to deliver innovative, breakthrough research and support programs that enable men to live happier, healthier and longer lives.

About Prostate Cancer Canada

Prostate Cancer Canada is the leading national foundation dedicated to the elimination of the most common cancer in men through research, advocacy, education, support and awareness. As one of the largest investors in prostate cancer research in Canada, Prostate Cancer Canada is committed to continuous discovery in the areas of prevention, diagnosis, treatment, and support.

For more information, please contact:

Adam Miller
Manager, Communications | Prostate Cancer Canada
Office: 416-441-2131 ext. 235
Email: adam.miller@prostatecancer.ca



Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

(TORONTO, Canada - Aug 7, 2017) -- Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50% of patient tumour samples.
More

Movember Foundation and Prostate Cancer Canada team up to turn research into results

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
More

Plaid for Dad participation skyrockets in third year

July 7, 2017 - TORONTO, ON - Launched for the first time in 2015, Prostate Cancer Canada's (PCC) Plaid for Dad campaign has further established itself as the way Canadians are choosing to give back on Father's Day weekend.
More


Click here for news archive